Information Provided By:
Fly News Breaks for February 22, 2019
EXAS
Feb 22, 2019 | 07:48 EDT
UBS analyst Daniel Brennan said his positive investment case on Exact Sciences is unchanged following its Q4 results. The analyst said his sales estimates will remain above consensus and he sees additional levers to help drive upside, including a greater ramp in test utilization, greater doctor additions, penetrating the 45-49 year cohort, and the retest opportunity. Brennan reiterated his Buy rating and $109 price target on Exact Sciences shares.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.